Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept, Madrigal Get Ready For NASH Commercialization

02 Mar 2023

• By Joseph Haas

liver — Intercept, Madrigal may be heading toward approval in NASH

Related Content

ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

16 Feb 2023

Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J

15 Feb 2023

Madrigal Phase III Success In NASH Spurs Buyout Speculation

19 Dec 2022

Viking Phase II Update Shows Sustained Response After Treatment’s End

28 Aug 2020

Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients

13 Aug 2020

Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations

09 Nov 2022

Intercept Gifts Shareholders With NASH Refiling

23 Dec 2022

Related Companies

Viking Therapeutics, Inc.

Intercept Pharmaceuticals, Inc.

Johnson & Johnson

Arrowhead Pharmaceuticals, Inc.

Novartis AG

Pliant Therapeutics, Inc.

Merck & Co., Inc.

NGM Biopharmaceuticals, Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

Pfizer Inc.

Additional Topics

Business Strategies Clinical Trials Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.